Efficacy and Safety of Besifovir Dipivoxil Maleate Compared With Tenofovir Disoproxil Fumarate in Treatment of Chronic Hepatitis B Virus Infection

Sang Hoon Ahn, Won Kim, Young Kul Jung, Jin Mo Yang, Jae Young Jang, Yong Oh Kweon, Yong Kyun Cho, Yoon Jun Kim, Gun Young Hong, Dong Joon Kim, Soon Ho Um, Joo Hyun Sohn, Jin Woo Lee, Sung Jae Park, Byung Seok Lee, Ju Hyun Kim, Hong Soo Kim, Seung Kew Yoon, Moon Young Kim, Hyung Joon YimKwan Sik Lee, Young Suk Lim, Wan Sik Lee, Neung Hwa Park, So Young Jin, Kyun Hwan Kim, Won Choi, Kwang Hyub Han

    Research output: Contribution to journalArticlepeer-review

    38 Citations (Scopus)


    Background & Aims: Besifovir dipivoxil maleate (BSV) has activity against hepatitis B virus (HBV). We performed a phase 3 study to compare the antiviral efficacy and safety of BSV vs tenofovir disoproxil fumarate (TDF) in patients with chronic HBV infection in Korea. Methods: We conducted a double-blind, non-inferiority trial of 197 patients with chronic HBV infection at 22 sites in South Korea, from November 2013 through February 2016. Patients were randomly assigned to groups given BSV (150 mg, n = 99) or TDF (300 mg, n = 98) for 48 weeks. We evaluated virologic responses to therapy (HBV DNA <69 IU/mL or 400 copies/ml), bone mineral density (BMD), and renal outcomes for safety analysis. The main efficacy endpoint was the proportion of patients with a virologic response at week 48. After 48 weeks, TDF was switched to BSV (150 mg) for an additional 48 weeks. Results: After 48 weeks of treatment, 80.9% of patients given BSV and 84.9% of patients given TDF met the efficacy endpoint, indicating the non-inferiority of BSV to TDF. At week 96, 87.2% of patients in the BSV–BSV and 85.7% of patients in the TDF–BSV had a virologic response. At week 48, changes in hip and spine BMD differed significantly between the BSV and TDF groups, whereas the estimated glomerular filtration rate in the TDF group was significantly lower than that in the BSV group. However, at 96 weeks, there were no significant differences in BMD and estimated glomerular filtration rate between the BSV-BSV and TDF-BSV groups. Conclusions: BSV has antiviral efficacy comparable to that of TDF after 48 weeks of treatment, with durable effects for 96 weeks. BSV has a better safety profile than TDF, in terms of bone and renal outcomes. ClinicalTrials.gov no: NCT01937806.

    Original languageEnglish
    Pages (from-to)1850-1859.e4
    JournalClinical Gastroenterology and Hepatology
    Issue number9
    Publication statusPublished - 2019 Aug

    Bibliographical note

    Funding Information:
    Conflicts of interest This author discloses the following: Dr Han reports grants from clinical trial sponsored by Ildong Pharmaceutical Co, Ltd outside of the submitted work. The remaining authors disclose no conflicts. Funding Supported by Ildong Pharmaceutical Company. This funding source had a partial role in study design, collection, analysis, and interpretation of data.

    Publisher Copyright:
    © 2019 AGA Institute


    • Acyclic Nucleotide Phosphonate
    • Drug Resistance
    • Nephrotoxicity
    • eGFR

    ASJC Scopus subject areas

    • Hepatology
    • Gastroenterology


    Dive into the research topics of 'Efficacy and Safety of Besifovir Dipivoxil Maleate Compared With Tenofovir Disoproxil Fumarate in Treatment of Chronic Hepatitis B Virus Infection'. Together they form a unique fingerprint.

    Cite this